Skye Bioscience to Participate in Upcoming Investment Conferences

About this update from Skye Bioscience, Inc.

[{"type":"text","content":"San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:","length":320,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Citi Global Healthcare Conference (Miami)1x1 meetings: Dec. 2","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Evercore Annual Healthcare Conference (Coral Gables)Fireside Chat: Dec. 3, 12:55 pm ET1x1 meetings","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Piper Sandler Annual Healthcare Conference (New York)Fireside Chat: Dec. 4, 11:30 am ET1x1 meetings","length":101,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":263,"olType":false},{"type":"text","content":"Available webcasts will be accessible on Skye's website.","length":60,"tagName":"p"},{"type":"text","content":"About Skye Bioscience ","length":21,"tagName":"p"},{"type":"text","content":"Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.","length":740,"tagName":"p"},{"type":"text","content":"CONTACTS","length":8,"tagName":"p"},{"type":"text","content":"Investor & Media [email protected](858) 410-0266","length":67,"tagName":"p"},{"type":"text","content":"LifeSci Advisors, Mike [email protected](617) 308-4306","length":70,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zen...

More updates from Skye Bioscience, Inc.